 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Danish biotech firm, Orphazyme (ORPH) said it will submit the enclosed proposal
  for a statutory restructuring plan to the Danish Maritime and Commercial High Court
  and to its...


Orphazyme to submit statutory restructuring plan to Danish court

---
- Orphazyme A/S ORPH has decided to withdraw its European Marketing Application for
  arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion
  by the CHMP scheduled for later this month. "Today's decision to withdraw the MAA
  enables us to consider the best possible path forward for arimoclomol," commented
  Orphazyme Chief Executive Officer Anders Vadsholt.


Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs

---
- InvestorPlace - Stock Market News, Stock Advice & Trading Tips
- After Orphazyme announced that it would withdraw the application for approval of
  its drug and delist its ADSs, ORPH stock is falling.
- The post Dear ORPH Stock Fans, Mark Your Calendars for March 31 appeared first on
  InvestorPlace...


Dear ORPH Stock Fans, Mark Your Calendars for March 31

---
- Danish biotech, Orphazyme (ORPH) announced on Tuesday that the company decided to
  withdraw the European Marketing Authorization Application for arimoclomol for the
  treatment of...


Orphazyme pulls European marketing application for lead candidate

---
- Orphazyme (ORPH) said the Danish Maritime and Commercial High Court began restructuring
  proceedings of the company on March 11.Earlier in March the company's board decided
  to file...


Orphazyme's restructuring proceedings begun by Danish court

---
- Zacks Investment Research upgraded shares of Orphazyme A/S (NASDAQ:ORPH  Get Rating)
  from a hold rating to a buy rating in a research report released on Tuesday , Zacks.com
  reports. They currently have $0.75 target price on the stock. According to Zacks,
  Orphazyme A/S is a late-stage ...


Orphazyme A/S (NASDAQ:ORPH) Upgraded to "Buy" by Zacks Investment Research

---
- InvestorPlace - Stock Market News, Stock Advice & Trading Tips
- The troubled biotech company's share price is up 40% despite plans to delist from
  the Nasdaq exchange and lay off 50% of its workers.
- The post Why Is Orphazyme (ORPH) Stock Up Today? appeared first on InvestorPlace...


Why Is Orphazyme (ORPH) Stock Up Today?

---
- Orphazyme (ORPH) ADRs have added more than 37% in early trading Thursday on above
  average volume as investors look past the recent operational issues of the Danish
  biotech that led to...


Orphazyme surges on above average volume

---
- Orphazyme ( ORPH -39.8%) stock plummeted after the company said it intends to delist
  its American Depositary Shares ((ADSs)) from Nasdaq and reduce its global workforce
  by ~50%.


Orphazyme stock slumps 40% as it plans Nasdaq delisting, halve workforce in restructuring

---
- 'Orphazyme A/S''s (NASDAQ: ORPH) board of directors has called for a court-mediated
  restructuring, prompting the second round of layoffs in less than a year. The in-...'


Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Watchers	11,509
52-Wk Low	$0.0002
52-Wk High	$7.48

Market Cap	$1.06M
Volume (M)	23,208.00
52-Wk High	$7.48
52-Wk Low	$0.0002

ORPH Orphazyme A/S - ADR

About

Feed

News

Fundamentals